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Background-—In this double-blind randomized placebo-controlled crossover trial, we investigated whether oral sodium nitrate,
when added to existing background medication, reduces exertional ischemia in patients with angina.
Methods and Results-—Seventy patients with stable angina, positive electrocardiogram treadmill test, and either angiographic or
functional test evidence of signiﬁcant ischemic heart disease were randomized to receive oral treatment with either placebo or
sodium nitrate (600 mg; 7 mmol) for 7 to 10 days, followed by a 2-week washout period before crossing over to the other
treatment (n=34 placebo-nitrate, n=36 nitrate-placebo). At baseline and at the end of each treatment, patients underwent modiﬁed
Bruce electrocardiogram treadmill test, modiﬁed Seattle Questionnaire, and subgroups were investigated with dobutamine stress,
echocardiogram, and blood tests. The primary outcome was time to 1 mm ST depression on electrocardiogram treadmill test.
Compared with placebo, inorganic nitrate treatment tended to increase the primary outcome exercise time to 1 mm ST segment
depression (645.6 [603.1, 688.0] seconds versus 661.2 [6183, 704.0] seconds, P=0.10) and signiﬁcantly increased total exercise
time (744.4 [702.4, 786.4] seconds versus 760.9 [719.5, 802.2] seconds, P=0.04; mean [95% conﬁdence interval]). Nitrate
treatment robustly increased plasma nitrate (18.3 [15.2, 21.5] versus 297.6 [218.4, 376.8] lmol/L, P<0.0001) and almost
doubled circulating nitrite concentrations (346 [285, 405] versus 552 [398, 706] nmol/L, P=0.003; placebo versus nitrate
treatment). Other secondary outcomes were not signiﬁcantly altered by the intervention. Patients on antacid medication appeared
to beneﬁt less from nitrate supplementation.
Conclusions-—Sodium nitrate treatment may confer a modest exercise capacity beneﬁt in patients with chronic angina who are
taking other background medication.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov/. Unique identiﬁer: NCT02078921. EudraCT number: 2012-
000196-17. ( J Am Heart Assoc. 2017;6:e006478. DOI: 10.1161/JAHA.117.006478.)
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C linicians are increasingly encountering patients withdiffuse coronary artery disease years after their revas-
cularization, when repeated intervention is either impossible
or of limited beneﬁt. Approximately 30% of “completely
revascularized” patients still continue to experience angina.1
Current antianginal drugs are very effective, but their use can
be precluded because of side effects (especially bradycardia
or hypotension).
Experimental evidence suggests that targeting the nitrate-
nitrite-nitric oxide pathway may have therapeutic potential in
patients with angina. Plasma nitrite is derived both from
oxidation of endothelium-derived nitric oxide and from dietary
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sources via bioconversion of nitrate involving an enterosali-
vary circulation, reduction by the oral microbial ﬂora, and low
stomach pH.2
The vasodilator effect of nitrite is potentiated by hypoxia3-6
and, unlike organic nitrates (eg, glyceryl trinitrate [GTN],
isosorbide 5-mononitrate, and isosorbide dinitrate), not sub-
ject to development of tolerance.7
Nitrate has been reported to improve metabolic efﬁciency
during exercise in human skeletal muscle, but it is unknown
whether this also occurs in cardiac muscle.8-12 Under
experimental conditions both nitrite and nitrate led to
protection from ischemia-reperfusion injury,13-17 blood pres-
sure reduction,18-21 reversal of pulmonary arterial hyperten-
sion,5,22,23 and induction of angiogenesis.24-26
In light of these preclinical experimental results we
hypothesized that oral sodium nitrate supplementation will
delay the onset of myocardial ischemia in patients suffering
from chronic angina.
Methods
Design
This randomized double-blind, placebo-controlled crossover
trial (Figure 1) was approved by the Scotland A Research
Ethics Committee, subject to Medicines and Healthcare
products Regulatory Agency regulation, and run in accordance
with the Declaration of Helsinki. All patients signed an
informed written consent.
Patient Selection and Protocols
Patients aged ≥18 years with exertional angina (≥2 months
duration) were recruited.
Inclusion criteria comprised a positive electrocardiogram
treadmill test (ETT) and either angiographic evidence of
obstructive coronary artery disease or, if not available, a
positive functional test (dobutamine stress echocardiogram
[DSE] or myocardial perfusion scan). Exclusion criteria were
inability to perform ETT, signiﬁcant valvular disease, nonsinus
rhythm, women of childbearing potential, G6PD (glucose-6-
phosphate dehydrogenase) deﬁciency, LV ejection fraction
<45% or New York Heart Association heart failure class III or
IV, myocardial infarction or coronary revascularization within
the past 2 months, resting ST segment depression ≥1 mm, or
left bundle branch block.
Patients were screened with modiﬁed Bruce-protocol ETTs
on separate days and enrolled only if they had replicable
difference (≤15%) in time to 1-mm ST segment depression
between the ﬁrst and the second screening.27
Patients continued regular medications including antiang-
inal agents at a ﬁxed dose with the exception of long-acting
organic nitrates, which were stopped at least 72 hours before
enrollment. The latter served to avoid potential interaction
between organic and inorganic nitrates, which partially act via
similar downstream pathways and may confound the out-
come. The use of short-acting sublingual GTN was allowed.
Some patients undergoing a concomitant DSE were asked to
omit their b-blocker for 48 hours before their visits (to
facilitate their dobutamine response) at the discretion of the
researcher, mainly depending on symptom severity, and
the elected strategy was used consistently throughout the
screening and all subsequent visits. This approach was
permissible due to the crossover design in which each patient
served as his or her own control.
Study Outcomes
The primary outcome was the time to a 1-mm ST segment
depression on ETT.
Secondary outcomes were time to chest pain onset, total
exercise time, angina and GTN use frequency, modiﬁed
Seattle Questionnaire, nitrate and nitrite plasma levels,
angiogenic markers, and myocardial contractility assessment
by peak systolic velocity measured by Doppler imaging
(details described elsewhere).28
Intervention and Randomization Process
The trial medication was manufactured and placed into packs
containing 2 bottles labeled 1 and 2 at the Western Glasgow
Inﬁrmary Pharmacy. Each bottle contained 14 capsules with
Clinical Perspective
What Is New?
• In patients suffering from chronic angina, sodium nitrate
treatment appears to have a modest anti-ischemic effect
when added to other background medication.
• We report a trend toward improved myocardial ischemia and
signiﬁcantly increased exercise capacity.
• Patients with stomach acid suppression appeared less likely
to beneﬁt, andmild nausea and vomiting were rarely reported.
What Are the Clinical Implications?
• Although there is currently not enough evidence to recom-
mend routine sodium nitrate supplementation to patients
with angina, increased dietary inorganic nitrate intake from
sources such as green leafy vegetables is unlikely to cause
any signiﬁcant side effects, may improve exercise capacity,
and can be recommended as a natural complement to other
medication in patients with chronic angina.
• The treatment period was relatively short, and a longer-term
supplementation trial will need to be established in future
studies.
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either 600 mg (7 mmol) of sodium nitrate or placebo (lactose
monohydrate).
Researchers and patients were blinded to the randomization
sequence in individual packs. Patients started treatment with
bottle 1, 1 capsule a day for a period of 7 to 10 days, before
undergoing a treadmill test and/or DSE and/or blood tests.
After a 2-week washout period the same procedure was
repeated with bottle 2. Compliance with medication was
assessed by patient via a checklist and by an investigator
calculating the remaining capsules from return bottles.28
Patients were asked to follow a low-nitrate and -nitrite diet,
limit caffeine intake, and avoid use of antibacterial
mouthwash.29 The 600-mg sodium nitrate dose was based on
previous evidence that 300 mg to 600 mg of oral nitrate was
effective in multiple studies assessing effects on blood pressure
and exercise capacity in human volunteers.10,11,20,21,30
Exercise Treadmill Test
Four ETTs, 2 screening and 1 following each treatment period,
were performed at the same time of day, in an air-conditioned
room (21°C), 2 hours following ingestion of the last study
capsule, on a CASE Exercise Testing System (GE Healthcare,
Chicago, IL). Automated blood pressure (BP) (Tango, SunTech
Figure 1. CONSORT diagram. DSE indicates dobutamine stress echocardiogram; ETT, electrocardiogram treadmill test; LBBB, left bundle
branch block; LVEF, left ventricle ejection fraction; STD, ST segment depression.
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Medical, Morrisville, NC) and 12-lead ECGs were recorded in a
standing position before exercise, at the end of each 3-minute
stage, at the time of ﬁrst 1-mm ST depression, at the time of
ﬁrst chest pain onset, at peak exercise, and every 3 minutes
into recovery. In patients with minor resting ST depression
(<1 mm), the time to 1-mm ST change was deﬁned as
additional ST depression of 1 mm below the resting value.31
A 1-mm ST depression was digitally detected and displayed by
the CASE software at the J point (+80 milliseconds).28
Dobutamine Stress Echocardiography
All patients were invited to participate in the DSE subgroup.
Details of the full protocol are provided elsewhere.28 In brief,
patients with inducible regional wall motion abnormalities and
satisfactory echowindowswho tolerated the baseline scanwere
enrolled. Exams were performed on a Vivid 9 machine (GE
Healthcare)2 hours after completion of the treadmill test. The
protocol involved acquisition at rest, baseline, and the following
stages with incremental dobutamine dose: 10, 20, 30, and
40 lg/kg per minute. For the screening test we used left
ventricle contrast (Sonovue, Bracco Imaging, Milan, Italy) in
order to improve sensitivity of detection of inducible regional
wall abnormalities.32 For on-treatment tests, images were
obtained without contrast using Doppler tissue velocity imaging
in apical views and later analyzed using Echo PAC (version
1.113; GEHealthcare). Longitudinal basal segment peak systolic
velocity was measured in 6 basal segments as previously
described.33 The percentage increase in peak systolic velocity at
peak dobutamine stage versus baseline was used for the ﬁnal
analysis. Differences in global and ischemic segment only (as
deﬁned on screening contrast test) were analyzed.28
Blood Tests, Modiﬁed Seattle Questionnaire, GTN
Use, and Angina Frequency
A subgroup of 20 patients underwent blood tests for nitrate
and nitrite levels and angiogenic markers (soluble fms-like
tyrosine kinase receptor-1, placental growth ractor, and
vascular endothelial growth factor) levels. Samples were
collected and analyzed as previously reported.34,28 We
modiﬁed the Seattle Questionnaire35 to reﬂect the short
treatment period of 1 week when compared to the original
assessment over 4 weeks. Frequency of angina attacks and
GTN use were documented on a checklist.
Statistical Analysis
In previous randomized studies of add-on antianginal medication
(amlodipine, organic nitrates, atenolol, ranolazine, ivabradine, or
allopurinol)27,36-39 the mean difference in time to 1-mm ST
depression between the active and placebo groups was
50 seconds. The SD in crossover studies was 80 to
90 seconds.36,40-42 Based on a mean treatment difference of
30 seconds and a SD of 80 seconds with a type I error of 5% and
statistical power 80%, we would require 58 patients. To allow for
dropouts we planned to randomize 70 patients. We sought to
recruit a minimum of 20 patients for the secondary end point of
DSE peak systolic velocity, and its sample sizing is described
elsewhere.28
The within-patient differences in primary and secondary
efﬁcacy end points were assumed to follow a normal distribu-
tion. The analysis followed recommendations by Senn43 for a 2-
treatment and 2-period crossover trial analysis. A general linear
model was constructed with the following factors included:
patient (as a random effect), period, and treatment (both as
ﬁxed effects). Treatment efﬁcacy was estimated as the
treatment effect estimate from the model with a 95%
conﬁdence interval and the hypothesis of 0 effect tested (5%
signiﬁcance level). An interaction term between treatment and
period was included to assess the possibility of a carryover
effect. Where this was statistically signiﬁcant (P<0.05), the
treatment effect estimate was also provided with this interac-
tion included in the model. The subgroup analysis (which was
not deﬁned before the analysis) was carried out in patients not
on proton pump inhibitors or H2 blockers. The assumption of a
normal distribution was checked via a graphic inspection of the
residuals. All analyses were carried out in SAS version 9.3 (SAS
Institute, Cary, NC) by a trial statistician who conducted and
reported the analyses subgroup blind.
Results
Recruitment and Baseline Characteristics
More than 1600 patients with a diagnosis of angina were
invited to participate. Following telephone or clinic interview
only 213 potentially suitable patients gave informed consent
and were invited for detailed screening investigations. Of
these 70 patients were found to be eligible and were
randomized (Figure 1, Table 1).44 With overall 93.6% of
patients taking all their capsules correctly as prescribed
(131 out of 140 treatment periods) the compliance was high.
All patients attending for their ﬁnal day visit took their last
capsules in the morning as planned (Data S1 and Table S1).
Electrocardiogram Treadmill Test
The time from the last nitrate capsule ingestion to start of the
treadmill test was 154.0 (139.5-169.3) minutes (median
[interquartile range]). During the nitrate treatment, relative to
placebo, there were trends toward reduction of various
manifestations of ischemia including time to 1-mm ST
depression, time to onset of chest pain, and total exercise
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time (Figure 2). However, only changes in total exercise time
were statistically signiﬁcant (median [95% conﬁdence interval]
760.9 [719.5, 802.2] versus 744.4 [702.4, 786.4] seconds,
P=0.04), whereas for time to 1-mm ST depression (661.2
[618.3, 704.0] versus 645.6 [603.1, 688.0] seconds, nitrate
versus placebo, P=0.10). There was a signiﬁcant treatment
and period interaction effect with respect to total exercise
time, but inclusion of this interaction term made no material
difference to the treatment effect estimate.
Post hoc subgroup analysis of the primary end point in
patients not on proton pump inhibitors or H2 blockers (n=43)
revealed a near-signiﬁcant increased time to 1-mm ST
depression in the nitrate arm (estimated effect size
+21.89 seconds, P=0.070) (Table 2).
Dobutamine Stress Echocardiography
Fifty-three patients underwent a screening DSE, 25 of whom
were enrolled into the DSE arm. Change in global systolic
velocity (baseline to peak) was not signiﬁcantly altered by
nitrate treatment (P=0.972) or when only ischemic segments
were analyzed (P=0.623) (Table 2).
Table 1. Demographics
Mean (SD) or n (%) All Subjects
Nitrate First
(n=36)
Placebo
First (n=34)
Age, y 67.3 (7.7) 66.5 (7.9) 68.3 (7.7)
Height, cm 168.0 (8.3) 169.8 (8.1) 166.2 (8.3)
Weight, kg 80.8 (13.6) 84.0 (14.6) 77.5 (11.9)
BMI 28.6 (4.0) 29.1 (4.6) 28.0 (3.4)
LVEF (%) 59.5 (7.1) 59.8 (6.8) 59.2 (7.5)
Systolic BP, mm Hg 140.1 (18.1) 137.2 (17.9) 143.3 (18.1)
Diastolic BP, mm Hg 79.4 (10.2) 78.9 (10.7) 80.0 (10.0)
Heart rate, bpm 61.9 (12.3) 60.8 (12.7) 63.2 (12.0)
Sex
Male 52 (74%) 31 (86%) 21 (62%)
Female 18 (26%) 5 (14%) 13 (38%)
CCS class*
1 29 (41%) 16 (44%) 13 (38%)
2 34 (49%) 17 (47%) 17 (50%)
3 7 (10%) 3 (9%) 4 (12%)
4 0 0 0
Ischemia test
Angio only 29 (41%) 16 (44%) 13 (38%)
Angio and DSE 30 (43%) 14 (39%) 16 (47%)
Angio, DSE, and MPI 3 (4%) 0 3 (9%)
Angio and MPI 2 (3%) 1 (3%) 1 (3%)
DSE only 6 (9%) 5 (14%) 1 (3%)
Vessel disease
Single vessel 23 (33%) 10 (28%) 13 (38%)
2 vessels 13 (19%) 8 (22%) 5 (15%)
3 vessels 12 (17%) 7 (19%) 5 (15%)
Residual disease† 17 (24%) 7 (19%) 10 (29%)
No angiography 5 (7%) 4 (11%) 1 (3%)
Previous MI 29 (41%) 13 (36%) 16 (47%)
HTN 36 (51%) 19 (53%) 17 (50%)
DM 21 (30%) 7 (19%) 14 (41%)
PAD 12 (17%) 6 (17%) 6 (18%)
Stroke or TIA 6 (9%) 2 (6%) 4 (12%)
Smoker
Never 32 (46%) 18 (50%) 14 (41%)
Ex-smoker 35 (51%) 17 (47%) 18 (53%)
Current 2 (3%) 1 (3%) 1 (3%)
Missing 1 (1%) 1 (3%)
Previous revascularization
None 39 (56%) 24 (67%) 15 (44%)
PCI 16 (23%) 5 (14%) 11 (32%)
CABG 8 (11%) 4 (11%) 4 (12%)
PCI and CABG 7 (10%) 3 (8%) 4 (12%)
Continued
Table 1. Continued
Mean (SD) or n (%) All Subjects
Nitrate First
(n=36)
Placebo
First (n=34)
Baseline medication
Aspirin 67 (96%) 34 (94%) 33 (97%)
b-Blocker 52 (74%)‡ 29 (81%) 23 (68%)
Long-acting
organic nitrate
27 (39%)§ 15 (42%) 12 (35%)
Ivabridine 2 (3%) 0 2 (6%)
Calcium channel
blocker
24 (34%) 11 (31%) 13 (38%)
Nicorandil 13 (19%) 4 (11%) 9 (26%)
Statin 62 (89%) 31 (86%) 31 (91%)
ACE-I 25 (36%) 16 (44%) 9 (26%)
ARB 13 (19%) 3 (8%) 10 (29%)
PPI 24 (34%) 12 (33%) 12 (35%)
H2 blocker 3 (4%) 1 (3%) 2 (6%)
Other 60 (86%) 33 (92%) 27 (79%)
ACE-I indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass graft;
DM, diabetes mellitus; HTN, hypertension; LVEF, left ventricle ejection fraction; MI,
myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary
intervention; PPI, proton pump inhibitor; TIA, transient ischemic attack.
*Canadian Cardiovascular Society Classiﬁcation of angina severity44.
†Previously revascularized multivessel disease with at least single-vessel residual disease
at time of angiography but unable to rule out progression of disease by the time of study
entrance.
‡b-Blockers were omitted in selected patients (18 [26%]) for 48 hours prior each visit to
facilitate dobutamine stress echocardiography; uninterrupted b-blocker treatment
continued in 34 (49%) patients.
§Oral long-acting nitrates were stopped before randomization in all participants.
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Modiﬁed Seattle Questionnaire, GTN Use, and
Angina Frequency
There was no signiﬁcant difference in the Modiﬁed Seattle
Questionnaire score, GTN use, or in angina frequency between
the treatment arms (Table 2).
Bloods
The time from the last nitrate capsule ingestion on the
morning of the visit to the blood test was 135.0 (129.3-157.5)
minutes (median [IQR]). Compared with placebo the nitrate-
treated arm had signiﬁcantly higher plasma nitrate (mean [SD]
18.3 [6.5] versus 297.6 [164.3] lmol/L, P<0.0001) and
nitrite (mean [SD] 346 [124] versus 552 [320] nmol/L,
P=0.003; Figure 3).
There was no signiﬁcant difference in angiogenic markers
between the placebo and nitrate arms (mean [SD] vascular
endothelial growth factor, 66.5 [65.3] versus 76.1 [87.2]
pg/mL, P=0.347; mean [SD] soluble fms-like tyrosine kinase
receptor-1, 216.1 [160.4] versus 182.0 [62.2] pg/mL, 0.321;
Figure 3).
Blood Pressure
There was no difference in BP obtained at rest (nitrate versus
placebo, systolic BP 132.4 [18.2] versus 131.3 [22.8] mm Hg,
P=0.670; diastolic BP 76.3 [11.0] versus 76.9 [13.2] mm Hg,
P=0.519) or at peak exercise (nitrate versus placebo, systolic
BP 175.3 [26.0] versus 173.0 [27.4] mm Hg, P=0.427;
diastolic BP 76.5 [12.2] versus 75.6 [12.6] mm Hg, P=0.626).
Adverse Events
In general the treatment was tolerated well. Gastrointestinal
side effects were more common in the nitrate arm (Table 3).
One patient reported severe vomiting following the capsule
intake for 3 consecutive mornings and was withdrawn from
the study.
Discussion
Sodium nitrate treatment added to other background medi-
cation failed to reach the predeﬁned level of statistical
signiﬁcance for the difference in the primary end point (time
to 1-mm ST depression). However, there was a trend to
improvement in this outcome and a statistically signiﬁcant
increase in the predeﬁned secondary end point, total exercise
time, supporting a modest anti-ischemic effect. All treadmill
test parameters trended to improve performance with nitrate
supplementation (Figure 2). On a post hoc analysis there was
a strong positive correlation among the time to 1-mm ST
depression, total exercise time, and time to chest pain onset
(Pearson r varied between 0.6 and 0.7, all P<0.001, Figures
S1 through S3).
The observed SD of difference in means of time to 1-mm
ST depression was in line with the SD used for our sample size
calculations. The sample size calculations assumed a mean
difference in this primary outcome measure of 30 seconds
based on previous trials in the ﬁeld. Although the estimate of
effect was indicative of a beneﬁt of nitrate (+16.21 [3.4 to
+35.8] seconds, effect estimate [95% conﬁdence interval]),
the difference did not reach statistical signiﬁcance. This may
be because there is indeed no beneﬁt or may reﬂect a more
modest beneﬁt than we had assumed in our sample size
calculations. The signiﬁcant increase in total exercise time
may support the latter conclusion. The population size that we
studied was substantially larger than those of previous
crossover studies investigating the effects of inorganic nitrate
on exercise or BP behavior, where typically cohorts of sizes
n=8 to 15 were sufﬁcient to show effects.11,21 Although there
was a trend to delay ischemia in the nitrate-treated group, the
increase of exercise capacity in our population may possi-
bly be due to an improvement of skeletal muscle function
se
co
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s
1-mm STD Chest Pain Exercise Time
500
600
700
800
900
nitrate
placebo
P=0.04P=0.34P=0.10
Figure 2. Exercise treadmill test. Columns display meanSEM time until either STD or
chest pain and duration of exercise. STD indicates ST segment depression.
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rather than a direct anti-ischemic cardiac effect. Improvement
of skeletalmuscle oxygen handling andmitochondrial efﬁciency
on exercise was previously described in healthy volunteers.8-12
Recently the SIRT3-AMPK-glut4 activation pathway, which is
associated with improved glucose handling in human skeletal
muscle, was demonstrated in volunteers with metabolic
syndrome.45 Coggan et al demonstrated in systolic heart
failure patients that a single dose of nitrate-rich beetroot juice
led to a signiﬁcant increase of skeletal muscle power.46
Furthermore, Zamani et al recently reported improved exercise
capacity in heart failure patients with preserved ejection
fraction.47 The effect was mainly due to reduction of vascular
resistance and increase of cardiac output on exercise.
In our study population there were no differences in
Modiﬁed Seattle Questionnaire, use of GTN, or angina
between treatment arms. It has to be noted that the latter
3 secondary outcomes were always felt to be particularly
weak end points for this particular study design; nevertheless,
we felt they should be reported. The treatment arms were
short, and angina episodes and GTN use were less frequently
reported than expected during the individual test weeks (<1
per treatment period, Table 2).
Nowadays, revascularization is performed rapidly after
listing for a procedure. Therefore, we elected a relatively short
treatment period (7 to 10 days) to avoid interference with
potential clinical revascularization plans. We cannot exclude a
greater effect with a longer treatment period.
Many of our patients were elderly, had multivessel disease,
and over years adapted their lifestyle to avoid angina. There
was a clear discrepancy between their infrequent subjective
reporting of angina despite objective severe disease, limiting
chest pain on treadmill testing, and electrocardigraphic and
echocardiographic evidence of inducible ischemia on func-
tional testing. Even patients who on screening in their own
description belonged to Canadian Cardiovascular Society
class III were objectively limited on exercise at low workload
but reported only 1 or even no angina episodes and little GTN
use during the test weeks later. Consequently, the study was
underpowered for these secondary end points. Despite
previous reports of proangiogenic markers in skeletal muscle
(animal model) and plasma in healthy volunteers, we observed
no increase in systemic proangiogenic markers in our angina
population.
In our study 7 mmol (600 mg) of sodium nitrate was given
daily for 1 week. Previously, single doses as low as 3.5 mmol
nitrate were effective in lowering blood pressure when given
to drug-naive grade 1 hypertensive volunteers.30 A single oral
dose of 4 mmol potassium nitrate was sufﬁcient to lower
blood pressure in healthy volunteers.20 A recent meta-
analysis showed that doses ranging from 300 to 600 mg
nitrate (either in the form of beetroot juice or sodium nitrate)
suggested a signiﬁcant moderate beneﬁt on time to exhaus-
tion.11 Larsen et al demonstrated in young healthy volunteers
that a daily dose of 0.1 mmol/kg given for 3 consecutive days
improved mitochondrial efﬁciency in skeletal muscle.10 The
dose used in our study is several times higher than an average
Western diet intake, which contains 100 mg/day.48 Our
patients ingested their last study capsule 2 to 3 hours
Table 2. Efﬁcacy End Points
N Nitrate Mean (SD) Placebo Mean (SD) Difference Mean (SD) Effect Estimate* (95% CI) P Value
Time to 1-mm ST depression (s) 67† 661.2 (179.0) 645.6 (177.2) 15.6 (80.9) 16.21 (3.4 to 35.8) 0.104
Time to chest pain (s) 49 576.9 (201.5) 563.5 (197.9) 13.4 (98.1) 13.56 (14.7 to 41.8) 0.343
Total exercise time (s) 67† 760.9 (172.7) 744.4 (175.4) 16.5 (69.5) 17.53 (0.6-34.3)
18.33 (1.5-35.2)
0.041
0.033
Global peak systolic velocity (% increase) 25 73.11 (33.1) 72.6 (31.7) 0.43 (31.0) 0.23 (13.1 to 12.6) 0.972
Ischemic segment peak systolic
velocity (% increase)
24 64.9 (43.4) 60.8 (36.4) 4.08 (29.2) 5.14 (15.5 to 25.8) 0.623
Seattle questionnaire score 64 101.8 (11.2) 102.7 (10.9) 0.9 (8.6) 0.90 (3.0 to 1.2) 0.406
Angina attack episodes 67 1.2 (2.5) 1.1 (2.2) 0.07 (1.4) 0.07 (0.30 to 0.43)
0.06 (0.30 to 0.43)
0.712
0.730
GTN use 67 0.6 (1.7) 0.5 (1.4) 0.09 (1.1) 0.09 (0.1 to 0.3)
0.09 (0.18 to 0.37)
0.514
0.490
Not taking PPI or H2 receptor blockers
Time to 1-mm ST depression (s) 43 662.1 (174.3) 641.0 (170.6) 21.0 (76.9) 21.8 (1.6 to 45.4) 0.070
CI indicates conﬁdence interval; GTN, glyceryl trinitrate; PPI, proton pump inhibitor.
*From linear model including period effect and also a treatment-period (ie, “carryover”) effect when this was found to be signiﬁcant (lower ﬁgures).
†Subject 66 missed both periods (withdrawn due to medication error); subject 46 (withdrawn due to nausea), and subject 181 missing second period (limiting chest pain before reaching
1-mm STD).
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before their treadmill test. This corresponds to peak plasma
nitrite following oral nitrate absorption and enterosalivary
bioconversion to nitrite.19,20,25 The increases in plasma
nitrate and nitrite are similar to those seen in studies
demonstrating a blood pressure–lowering effect. Although it is
possible that a higher dose might have been more effective,
this could also have potentially increased side effects.
We observed gastrointestinal side effects (usually mild)
relatively frequently (Table 3). There were no reports of
gastrointestinal adverse events in a meta-analysis of 17
studies assessing nitrate’s effects on BP and another meta-
analysis of 16 studies assessing its effects on exercise
capacity.11,21 However, the majority of these studies were not
formal clinical trials of investigational medicinal products
requiring reporting of adverse events, and consequently, there
might have been underreporting.
Furthermore, most participants in previous studies were
young healthy volunteers. Elderly overweight, sedentary
patients on polypharmacy are more likely to suffer from
chronic esophageal reﬂux disease or peptic ulcerative
disease. In line with this, a signiﬁcant proportion (38%) of
our angina patients were taking proton pump or H2 inhibitors.
Upper gastrointestinal side effects were well known when
much higher doses of inorganic nitrates or nitrites were used
for angina treatment at the beginning of the 20th century.49
We did not observe the BP-lowering effect previously
observed in healthy young volunteers19 and in nonobese drug-
naive grade I hypertensives,30 but other studies have
suggested that this effect may be absent in obese elderly
subjects with insulin resistance.50,51 Our study population had
end-organ cardiovascular disease and high BMI (28.64.1)
kg/m2; most were hypertensives and were taking regular
background medication.
Another important factor is the polypharmacy these
patients were on. Gilchrist et al studied patients with type 2
diabetes mellitus and hypertension (many on antihyperten-
sives), and, unlike with studies in healthy volunteers, they
observed no effect of nitrate therapy on the oxygen cost of
submaximal exercise.50 Our study patients were frequently on
antihypertensive treatment (Table 1). In metabolic syndrome,
a dysregulation of nitric oxide signaling may interfere with
efﬁcacy of some conventional drugs used; on the other hand,
certain medications such as statins, angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, or b block-
ers may exert their therapeutic effects via modulation of nitric
oxide signaling.52 Under such circumstances traditional
medications may weaken the effect of nitrate supplementa-
tion. This may be a reason why other investigators saw more
pronounced vasodilator effects even in the elderly population
when they chose fairly healthy subjects with no background of
antihypertensive drugs. Medications or other underlying
medical conditions that alter the gastric pH,53-55 saliva
production, oral bacteria, or intestinal bacterial ﬂora may
affect the effectiveness of nitrate treatment. A subgroup
analysis of patients who were naive of stomach acid–
suppressing medication in our study showed a stronger trend
to anti-ischemic efﬁcacy in our study (see Table 2), supporting
the recent concern that antacids may impact on the efﬁciency
of inorganic nitrate–based management in humans54,55 by
preventing the bioactivation of nitrite to nitrous acid (HNO2) in
the stomach.56
It is difﬁcult to prove antianginal effects in patients on
multiple background medications. Although our ﬁndings
Figure 3. Plasma levels of (A) nitrate, (B) nitrite, (C) VEGF, and (D) sFlt-1. Data are displayed as meanSEM. sFlt indicates soluble fms-like
tyrosine kinase receptor; VEGF, vascular endothelial growth factor.
Table 3. Adverse Events
n (%) Nitrate Placebo
Nausea/abdominal cramps 6 (9%) 3 (4%)
Vomiting 3 (4%) 0
Dry mouth 1 (1%) 1 (1%)
Tiredness 1 (1%) 1 (1%)
Hot flushes 1 (1%) 1 (1%)
Headache 0 3 (4%)
Loose stool 0 1 (1%)
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indicate at most modest effects of nitrate when it is given as
add-on therapy, we cannot rule out a stronger beneﬁt if given as
a monotherapy. However, we believe that the strength of our
study lies in the analysis of real-life clinical scenarios including
patients with multiple comorbidities on polypharmacy. The
crossover design made it possible to account for this variation.
Chronic angina patients would be very unlikely to be treated
with inorganic nitrate monotherapy in the presence of potent
ﬁrst-line anti-anginals, and similar studies would be ethically
difﬁcult to defend. In this context, it is quite exciting that a
dietary treatment strategy has modest beneﬁts on exercise
capacity without lowering BP or heart rate. No current
standard antianginal medication offers any prognostic beneﬁt
for the patients. In the context of a trend to increased time to
1-mm ST depression and a signiﬁcantly increased total
exercise capacity together with the well-described prognostic
beneﬁt of a nitrate-rich Mediterranean diet or the fruit- and
vegetable-rich DASH diet,2,48,57 it appears appropriate to
recommend that angina patients adhere to the above diets.
Although the treatment period was relatively short (in order to
avoid interference of natural disease progression on the
outcome analysis in this crossover design), the supplementa-
tion resulted in better exercise performance. The results of a
longer-term supplementation will need to be established in
further studies. Although rare and usually mild, nausea and
vomiting were reported. Patients ought to be alerted to this
possible adverse effect.
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Data S1. 
Compliance 
The length of capsule treatment was set per protocol to 7-10 days before the test visits to 
accommodate for patient’s non-study commitments, short term appointment changes or weekends 
which may prohibit the patient to attend. In the vast majority, in 89% (123) of all on-treatment visits 
the patients were planned to take eight capsules (e.g Tuesday morning to Tuesday morning). In 7% 
(10) of visits seven capsules, in 3% (4) of visits 9 capsules and in 0.7% (1) of visits 10 capsules were 
taken prior to the study tests. The compliance with prescribed treatment was very high.  
Overall 93.6% of patients took their capsules correctly as prescribed (131 out of 140 treatment 
periods). On three (2.1%) visits patients missed one capsule intake when counterchecked by the 
investigator. However on every single occasion patients took their last treatment capsule on the 
morning visit prior to the tests which was verbally confirmed on their visit. 
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Table S1. Compliance 
Compliance 
Investigator calculated 
 
 
Correctly completed treatment periods 
Missed one capsule*  
131 
3 
Took one additional capsule* 1 
Failed to return bottle£  3 
Dropped out due to AE  2    (one due to vomiting, one not related to IMP) 
Total treatment periods  140 
*in one treatment period (but last capsule was always taken); £ patient forgot to return the 
treatment bottle (but they confirmed intake by filling a checklist) 
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We performed an unblinded post hoc-analysis of the exercise treadmill test data correlating the paired 
differences (nitrate treatment minus placebo treatment data) between the main treadmill test outcomes 
against each other using Pearson correlation. There was a strong positive correlation between the time 
to 1mm ST depression, total exercise time and time to chest pain onset (all p< 0.001): 
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Figure S1. Correlation between the differences of paired treatment arms of total exercise time and 
time to 1mm ST depression (STD) 
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Time to chest pain difference, sec
[nitrate-placebo]
E
xe
rc
is
e
 t
im
e
 d
if
fe
re
n
c
e
, 
s
e
c
[n
it
ra
te
-p
la
c
e
b
o
]
-200 200 400
-200
-100
100
200
300
Pearson r = 0.679
p < 0.001
 
 
Figure S2. Correlation between the differences of paired treatment arms of total exercise time and 
time to chest pain onset 
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Figure S3. Correlation between the differences of paired treatment arms of time to chest pain onset 
and time to 1mm ST depression (STD) 
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